Merck & Co Inc

NYSE:MRKUnited States

Today

Show headlines and story abstract

• DJ CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com, from 8 hours ago by Dow Jones

  8 hours ago by Dow Jones
  Companies Mentioned: MRK, PH
  
  By Jacob Sonenshine
  
  CEOs are hungry to make deals -- and there are more to come.
  
  Mergers and acquisitions worldwide are expected to climb 6% this year, on pace to hit almost $3.1 trillion, according to the London Stock Exchange Group. The bump comes after a rough 2023: Deals totaled about $2.9 trillion, nearly half of 2021's post-pandemic peak of close to $6 trillion.
  

• DJ CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com, from 8 hours ago by Dow Jones

  8 hours ago by Dow Jones
  Companies Mentioned: MRK, PH
  
  By Jacob Sonenshine
  
  CEOs are hungry to make deals -- and there are more to come.
  
  Mergers and acquisitions worldwide are expected to climb 6% this year, on pace to hit almost $3.1 trillion, according to the London Stock Exchange Group. The bump comes after a rough 2023: Deals totaled about $2.9 trillion, nearly half of 2021's post-pandemic peak of close to $6 trillion.
  

• DJ Merck Price Target Maintained With a $155.00/Share by Cantor Fitzgerald, from 11 hours ago by Dow Jones

  11 hours ago by Dow Jones
  Companies Mentioned: MRK
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MRK/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 03, 2024 11:20 ET (15:20 GMT)
  

• Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More, from 14 hours ago by PR Newswire

  14 hours ago by PR Newswire
  Companies Mentioned: GSK, JNJ, MRK, ANVS

  NetworkNewsWire Editorial Coverage

  Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients suffering from historically challenging diseases. Alzheimer's disease (AD) for example, has become a focal point of this innovation, with recent U.S. Food and Drug Administration (FDA) approvals of Leqembi and Kisunla — although these treatments only slow cognitive decline rather than improve cognitive function. New uses for approved glucagon-like peptide-1 (GLP-1) and phosphodiesterase 5 (PDE5) inhibitor drugs show promise in treating Alzheimer's, with companies such as Annovis Bio Inc. (NYSE: ANVS) (profile) leading the way with treatments ready for late-stage clinical trials. Beyond Alzheimer's, the pharmaceutical industry is experiencing a surge of innovation across various disease areas. Major players, including Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK) and GSK plc (NYSE: GSK) are at the forefront of medical innovation, tackling previously intractable diseases.

• Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More, from 14 hours ago by Dow Jones

  14 hours ago by Dow Jones
  Companies Mentioned: MRK
  
  Novartis (NYSE: NVS) is an innovative medicines company with research and development at its core. The company's R&D engine powers an industry-leading pipeline that is focused on delivering transformative medicines to fight disease, restore possibility and help people live life on their own terms. The company's researchers work across several diseases areas to drive drug discovery and early development, while its development organization leads the advanced clinical development of those medicines. This work is powered by technology platforms that help the company innovate across its core therapeutic areas: cardiovascular, renal and metabolic, oncology, immunology and neuroscience.